Helicobacter pylori Infection: From Pathogenesis to Clinical Management

Noor Adnan Mahmood (College of Education for Pure Sciences, College of Science, Tikrit University)
Olfat Raouf Mahmoud (College of Education for Pure Sciences, College of Science, Tikrit University)
Lubna Arkan Younis (College of Education for Pure Sciences, College of Science, Tikrit University)

Academia Open
Vol. 11 No. 1 (2026): June

General Background: Helicobacter pylori represents a gram-negative bacterium colonizing gastric mucosa in approximately half of the global population, recognized as the primary causative agent of chronic gastritis, peptic ulcer disease, gastric cancer, and mucosa-associated lymphoid tissue lymphoma. Specific Background: The bacterium employs sophisticated virulence factors including cytotoxin-associated gene A and vacuolating cytotoxin A to establish chronic infection, triggering persistent inflammatory responses that progress through atrophic gastritis, intestinal metaplasia, and dysplasia toward malignancy. Knowledge Gap: Despite advances in understanding pathogenesis and treatment protocols, escalating antibiotic resistance threatens conventional eradication strategies, necessitating comprehensive evaluation of current diagnostic approaches and therapeutic interventions. Aims: This review systematically examines the microbiology, pathogenesis, epidemiology, clinical manifestations, diagnostic methods, and treatment strategies for H. pylori infection, with particular emphasis on antibiotic resistance patterns. Results: Evidence demonstrates that bismuth-based quadruple therapy achieves 80-90% eradication rates even in clarithromycin-resistant regions, while H. pylori eradication significantly reduces gastric cancer risk when implemented before precancerous lesion development. Novelty: The analysis integrates molecular resistance mechanisms with population-based epidemiological patterns to inform personalized treatment selection. Implications: Sustained multidisciplinary collaboration remains essential for developing novel antibiotics, rapid susceptibility testing, and effective vaccines to reduce global H. pylori disease burden.Keywords : Helicobacter Pylori, Gastric Cancer, Peptic Ulcer Disease, Antibiotic Resistance, Diagnostic MethodsHighlight : Bacterium infects approximately 4.4 billion individuals worldwide with varying regional prevalence rates. Clarithromycin resistance reaches 50% in some regions, reducing triple therapy effectiveness significantly. Early eradication prevents gastric cancer progression when administered before precancerous lesion onset.